Objective: To evaluate if molecular markers of eosinophilia in olfactory-enriched mucosa are associated with olfactory dysfunction. Study Design: Cross-sectional study of tissue biopsies from 99 patients, and an additional 30 patients who underwent prospective olfactory testing prior to sinonasal procedures.
INTRODUCTION
Chronic rhinosinusitis (CRS) is a common inflammatory condition that affects approximately 30 million Americans. 1 This diagnosis includes both CRS with nasal polyps (CRSwNP) and CRS without nasal polyps (CRSsNP). Many CRS patients, especially those with CRSwNP, are affected by olfactory impairment. 2 Traditionally, mucosal edema leading to nasal obstruction, and ultimately to decreased airflow to the olfactory cleft, was advanced as the etiology of CRS-associated olfactory loss. 3 This theory is challenged by data suggesting that the degree of anosmia is not correlated with the degree of resistance to nasal airflow, and that removal of polyps does not reliably improve olfaction despite improvement in airflow. 4 In addition, histologic studies of olfactory mucosa in patients with CRS have demonstrated changes in the olfactory epithelium, including hyperplasia of goblet cells, squamous metaplasia, and olfactory epithelium erosion that are correlated with olfactory dysfunction. 2, 5 Due to these findings, there is qualitative evidence that olfactory dysfunction also has a sensorineural component. Because eosinophil degranulation products such as eosinophilic cationic protein (ECP) and eosinophil-derived neurotoxin are known to directly modulate neuronal function, 6, 7 we hypothesized that molecular markers of eosinophilia would specifically be locally elevated in olfactory neuroepithelium-bearing tissue and would correlate with CRS-associated olfactory loss (Fig. 1) .
The human olfactory neuroepithelium (ON) is located in a region called the olfactory cleft, primarily on the superior turbinate (ST) and more variably on regions of the upper-middle turbinate and septum. [8] [9] [10] [11] Specific markers for olfactory neurons include olfactory marker protein (OMP) and growth-associated protein 43 (GAP-43). The inferior turbinate (IT) is not known to have ON but has respiratory epithelium. 12 In this study, we characterize the nature of inflammation in the ST of patients with CRS and compare molecular biomarkers of eosinophilia with the performance on current clinical measures of olfactory function.
MATERIALS AND METHODS

Patients
Specimens were first obtained from a tissue repository obtained from patients with CRS who underwent primary or revision endoscopic sinus surgery (ESS), and from control patients without evidence of CRS who were undergoing septoplasty or skull base tumor resection by participating Northwestern University Feinberg School of Medicine Otolaryngologists. The anatomic location of assessed tissue biopsies included the IT, ST, and nasal polyps. In patients undergoing ESS/skull base tumor resections, superior turbinate biopsies were obtained in the course of routine sphenoidotomy, as previously described. 13, 14 Biopsies of the superior turbinate from control patients not undergoing ESS were obtained using a pediatric through-cut forceps, which was consistent with previously published studies involving olfactory biopsies. 15 These studies have demonstrated that olfaction remains unaffected following these small biopsies. Collection of specimens from this subset of patients was single-sided and corresponded to the side selected for olfactory testing. Patients were excluded if they had any history of trauma or tumor-associated anosmia. The Northwestern University Institutional Review Board reviewed the study protocol and approved the study. Informed consent was obtained from all participants in the study.
Real Time PCR
RNA extraction from nasal and sinus tissue was performed using QIAzol (Qiagen, Valencia, CA), as previously described. 16 All material was treated with DNAse to eliminate genomic DNA contamination. RNA quality was determined using the 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA) and the Taqman method for quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) (Applied Biosystems, Grand Island, NY) was performed. Specimens were initially analyzed using a panel of gene expression markers for eosinophils (CLC: Hs01055743_m1), neutrophils (CXCR1: Hs01921207_s1), mast cells (tryptase: Hs02576518_gH), T-cells (CD3: Hs99999153_m1), and leukocytes (CD45: Hs04189704_m1). However, analysis suggested the eosinophil marker CLC was most relevant; subsequent specimens were only analyzed for CLC, the cytokine IL-5 (Hs01548712_g1), the chemokine eotaxin-1/CCL11 (Hs00237013_m1), and the olfactory neural markers OMP (Hs01087269_s1) and GAP-43 (Hs00967138_m1). All cycle threshold (Ct) values were normalized to the b-glucuronidase (GUSB) housekeeping gene (Hs00939627_m1) using the delta Ct method because this previously was found to be the most consistently expressed housekeeping gene. 17 Samples for which the gene of interest remained undetectable after 40 cycles assigned a Ct value of 40. A specimen was considered to contain olfactory neuroepithelium if the DCt was less than the lower limit of the 95% confidence interval (CI) of the mean for IT specimens.
ECP Measurement in Sinonasal Tissue
In specimens for which sufficient tissue sample was available for protein analysis in addition to (qRT-PCR) analysis, homogenates were prepared and analyzed for ECP using ELISA (MBL, Nagoya, Japan) according to manufacturer's instructions, as previously described. 18 Per laboratory protocol, ECP levels were normalized to total protein, and only samples achieving a total protein of 0.5mg/mL were analyzed.
Olfactory Function Test
After preliminary data was obtained using qRT-PCR analysis of repository specimens, consecutive patients were recruited in the second phase of the study to undergo olfactory testing. Subjects were administered two separate tests prior to surgery and specimen retrieval: one of olfactory threshold and one of olfactory discrimination. Olfactory threshold was determined by one of two trained personnel on the 1-to 16-point score by the Sniffin' Sticks (Burghart, Wedel, Germany) n-butanol threshold test, according to manufacturer instructions. 19, 20 A modification to designate a score of "0" to those unable to smell the most concentrated marker was added. Olfactory discrimination was determined by the University of Pennsylvania Smell Identification Test (UPSIT) (Sensonics, Haddon Heights, NJ), which is a 40-item forced choice test. 21 Prior to initiating either test, a wetted Merocel sponge (Mercocel, Mystic, CT) was placed in one nostril to isolate a single side for testing. The left nostril was selected for testing in all patients unless anatomical nasal obstruction prevented passage of air on that side. The side selected was communicated to the surgical team such that all biopsy specimens were obtained from the side where olfactory testing was performed. At the completion of testing, the patient's raw score was recorded and compared to the published data on the age-and sex-matched median scores. 9, 22 To account for published nonlinear age-and sex-specific performance on olfactory testing, we subtracted the subject's score from the ageand gender-matched mean. Using this metric, a score close to 0 represents normal olfaction, whereas more negative scores denote worse olfactory function. In addition to objective testing, patients completed the Sino-Nasal Outcome Test-22 (SNOT-22) questionnaire of patient-perceived symptoms in sinusitis. 23 The SNOT-22 score is scored between 0 and 110, with average reported SNOT-22 scores in normal controls being 9.
24
CT and Endoscopic Analysis
Preoperative computed tomography (CT) scans were also evaluated for all patients with CRS who underwent olfactory testing. Coronal images of both the anterior olfactory cleft, which was defined by the first image containing the heads of both middle turbinates, as well as the posterior olfactory cleft, which was defined by the first image containing the heads of both superior turbinates, were extracted and placed into a separate document. In these images, all other sinuses were cropped out such that all that was visible was the olfactory cleft on the test side. A third party removed all identifying information and assigned a random number to each pair of images prior to analysis. The images were then analyzed by two separate physicians and scored in both the anterior and posterior cleft. Anterior cleft scoring was on a scale of 1 to 4, with 1 (< 25% opacification), 2 (25%-50% opacification), 3 (51%-75% opacification), and 4 (> 75% opacification) similar to the methods of a published study. 25 Posterior cleft was scored on a scale of 1 to 4, with 1 (both surfaces of superior turbinate visible), 2 (one surface of superior turbinate visible), 3 (neither surface of superior turbinate visible, incomplete opacification) and 4 (neither surface of superior turbinate visible, complete opacification).
At the time of surgery, endoscopic images were obtained from the middle meatus and the olfactory cleft. Olfactory cleft images were obtained by superiorly directing the endoscope medial to the middle turbinate. As with CT images, a third party removed all identifying information and assigned a random number to each pair of images prior to analysis. Two separate physicians used the same grading scale as the CT images scored the images of the olfactory cleft.
Statistical Analysis
Analysis was performed using GraphPad Prism (GraphPad, Version 6, La Jolla, CA). One-way analysis of variance (ANOVA) analysis was used for analyses comparing multiple specimen/disease groups, with post-hoc pair-wise Tukey adjustment when significant results were found on ANOVA. Pearson correlation coefficients were determined with r and P values reported. Univariate and multiple linear regression was performed using SPSS (IBM Corp, Version 22, Armonk NY). In the multiple linear regression model, all clinical factors with P < 0.2 were included in models for age-and sex-adjusted olfactory threshold and discrimination scores. Colinearity diagnostics were performed using the variance inflation factor. A value of P < 0.05 was deemed to be statistically significant.
RESULTS
Demographic Information
Sinonasal and polyp tissues were obtained from 26 controls, 37 patients with CRSsNP, and 36 patients with CRSwNP, and were studied using qRT-PCR. Tests of olfaction were performed on seven controls, 10 patients with CRSsNP, and 13 patients with CRSwNP prior to collection of specimens. Due to the small size of the biopsies, particularly from ST tissue, simultaneous protein analysis was available in 50 of the studied specimens. Subject characteristics are shown in Table I . Of the 30 patients who had prospective olfactory testing, 29 completed the UPSIT testing (Sensonics), whereas 25 completed the Sniffin' Sticks (Burghart) test. Complete olfactory testing data was not always available because some patients declined further testing, particularly due to the additional time required and concentration-intensive nature of threshold testing.
qRT-PCR Characterization of Markers of Inflammation, Th2 Cytokines
To compare the association between markers of inflammation in ST tissue from patients with CRS and controls, qRT-PCR analysis of markers for eosinophils (CLC), neutrophils (CXCR1), T-cells (CD-3), mast cells (tryptase), and leukocytes (CD45) were completed on an initial set of specimens. These demonstrated that only CLC showed significant elevation in CRSwNP or CRSsNP ST tissues compared to control ST tissue, and further analysis on the other markers were discontinued (data not shown). We then assessed expression of the eosinophilassociated molecules CLC, IL-5, and Eotaxin-1 on specimens from a total of 99 subjects. CLC expression in ST tissue from CRSwNP patients was significantly elevated compared with ST and IT tissue in CRSsNP and control patients (all P < 0.001) ( Fig. 2A) . Polyp tissue had higher expression of CLC compared to ST (P < 0.001) and data are provided for reference. IL-5 expression was elevated in ST tissue of both CRSsNP and CRSwNP relative to both IT and ST tissue in controls (P 5 0.01-0.0001) (Fig. 2B) .
Interestingly, eotaxin-1 was not elevated in ST tissue relative to other sinonasal tissue; however, it was elevated in polyps (Fig. 2C ). There was a significant moderate positive correlation between IL-5 and CLC gene expression in the ST tissue from all patient groups (P < 0.001, r 5 0.65) (Fig. 3A) . Despite insignificant elevations of eotaxin-1 in ST in CRSwNP, there was a weak but significant correlation with CLC expression in ST tissue (P < 0.0001, r 5 0.49) (Fig. 3B) . Interestingly, these same correlations were not significant in polyp tissue (data not shown).
ECP Analysis and Correlation With CLC Gene Expression
ECP levels were studied on available homogenates primarily to validate CLC gene expression as a biomarker of eosinophils. We found significantly higher ECP levels in CRSwNP ST compared to CRSsNP ST (P < 0.01) and control IT (P < 0.05). There was a strong and highly significant correlation between CLC gene expression and ECP protein levels (P < 0.001, r 5 20.76) (Fig. 3C ).
Olfactory Gene Expression in ST Tissue
We next used qRT-PCR to verify the enrichment of olfactory tissue in our samples. IT samples (not anticipated to contain olfactory tissue) were tested to determine the mean and 95% CI of gene expression in nonolfactory tissue. Using this 95% CI, we then assessed expression of ON markers in ST samples. The presence of ON was defined as expression of GAP-43 and OMP expression above that of the upper limit of the 95% CI of IT biopsies. We found that 29 of 49 (59%) of ST samples contained ON based on their expression of the immature olfactory neuronal marker, GAP-43, and 21 of 49 (43%) of ST samples contained ON based on their epression of the mature olfactory neuron marker, OMP. CRSsNP 5 chronic rhinosinusitis without nasal polyps; CRSwNP 5 chronic rhinosinusitis with nasal polyps; CT 5 computed tomography; F 5 female; IT 5 inferior turbinate; M 5 male; N 5 no; P 5 polyp; PCR 5 polymerase chain reaction; ST 5 superior turbinate; SNOT-22 5 Sino-Nasal Outcome Test-22; U 5 unknown; Y 5 yes; yr 5 year. Fig. 2 . Relative expression of RNA markers of (A) CLC, a marker for eosinophils; (B) IL-5; and (C) Eotaxin-1 in superior and IT tissue in normal controls, patients with CRSsNP, and with CRSwNP. In this representation, more negative numbers signify higher concentrations of CLC. For reference, relative expression of these markers is also shown in polyp tissue. **P < 0.01, *** P < 0.001, **** P < 0.0001. CLC 5 Charcot Leyden crystal protein; CRSsNP 5 chronic rhinosinusitis without nasal polyps; CRSwNP 5 chronic rhinosinusitis with nasal polyps; ct 5 cycle threshold; IT 5 inferior turbinate; ST 5 superior turbinate.
Olfactory Testing Results
Analysis of olfactory threshold performance using Sniffin' Sticks (Burghart), revealed the age-and sex-adjusted olfactory threshold mean was 25.69, 24.27, and 20.91 for CRSwNP, CRSsNP, and controls, respectively (P < 0.01). Similar to olfactory threshold, the average age-and sexadjusted mean for olfactory discrimination, as determined by the UPSIT (Sensonics) was 214.5, 26.36, and 21.89 for CRSwNP, CRSsNP, and controls, respectively (P < 0.01). There was a significant modest correlation between the severity of the smell/taste loss item on the patient-reported SNOT-22 questionnaire and the age-adjusted olfactory discrimination and olfactory threshold scores (r 5 0.73, P < 0.01 for both correlations, data not shown).
Comparison of Preoperative Olfactory Testing to Tissue CLC Expression and Clinical Measures of Obstruction
When the age-adjusted Sniffin' Sticks (Burghart) olfactory threshold scores were compared to the DCt CLC in ST, a statistically significant moderate correlation was found (P 5 0.002, r 5 0.57), with worse performance on the test being associated with higher CLC levels (Fig. 5A) . Similarly, there was a positive correlation between UPSIT (Sensonics) performance and DCt CLC in ST (P 5 0.02, r 5 0.42) (Fig. 5B) . Next, univariate and multiple linear regression were performed of atopy status, polyp status, endoscopic observations of obstruction, CT opacification, and CLC. On univariate analysis, multiple factors were significantly correlated with olfactory threshold and discrimination (Table IIa: threshold; Table IIb : discrimination). On multivariate regression, both models significantly modeled olfactory performance (r 5 0.83 and r 5 0.80 for threshold and discrimination, respectively). However, only CLC expression was significantly correlated with olfactory threshold after adjusting for the other clinical factors (Table IIa) ; none of the individual items was significantly correlated with discrimination. The variance inflation factor did not raise significant concerns of collinearity.
DISCUSSION
Chronic rhinosinusitis, especially CRSwNP, has been associated with olfactory impairment. To date, the exact etiology of the alteration in smell threshold; discrimination in CRS in humans is unknown and unlikely only to be related to a loss of airflow. 4, 26 In mouse models by Lane et al., TNF-a-induced olfactory inflammation impaired olfactory function, but the role of this cytokine in CRS-associated olfactory loss in vivo has not been confirmed. 27, 28 In our study, we found that eosinophilic infiltration, as measured by gene expression of CLC, was elevated in biopsy specimens of ST tissue in patients with CRSwNP compared to those from CRSsNP and non-CRS controls (Fig. 2) . The selection of CLC as a marker was supported by its highly reliable correlation with eosinophilic asthma, celiac disease, and CRS, with published correlations with cytokines associated with eosinophilic inflammation in sinonasal tissue. [29] [30] [31] [32] There was striking regional variation in CLC expression in the nasal passages of patient with CRSwNP. Unlike NP tissue, which was mostly eosinophilic, ST had a large range of eosinophilia but was still significantly higher than the ST of control and CRSsNP patients, as well as IT biopsies from patients with CRSwNP, CRSsNP, and controls. This is in contrast to markers for neutrophils (CXCR1), T-cells (CD3), mast cells (tryptase), and leukocytes (CD45), which were not elevated in ST tissue of CRSwNP patients compared to ST from control and CRSsNP patients. We further found that CLC gene expression correlated with the cytokine IL-5 and the chemokine eotaxin-1 (CCL11), suggesting CLC is reflective of type 2 eosinophilic inflammation (Fig. 3) . CLC gene expression was also strongly correlated with ECP protein levels, a more widely used eosinophil granule protein, thus validating its utility for measuring eosinophilia using gene expression. Given these findings, we tested the hypothesis that local CLC gene expression in ST tissue would be related to the olfactory impairment most commonly found in CRSwNP patients. We found several clinical, radiographic, and endoscopic measures, as well as CLC gene expression, were significantly correlated with olfactory threshold on univariate analysis, but only CLC expression remained significant on multivariate testing (Table IIa) (Fig. 5) .
Although ON is variably distributed in the superior aspects of the middle turbinate and upper septum, the ST was selected as an anatomically standardized biopsy site due to its high concentration of ON and because it is partially resected in the course routine endoscopic sinus surgery. 8, 10, 11, 33 Indeed, our study finds elevated expression of olfactory neuronal markers, including GAP-43 and OMP, at rates similar to those previously described in the literature using histological methods (Fig. 4) . 2, 5, 9 Previous studies of olfactory tissue in CRS by Yee et al. used histopathology specimens collected from the ON rich upper septum to demonstrate that squamous metaplasia and mucosal erosion were more common and severe in patients with CRS when compared to normal patients. 2 A separate study by Kern, using histopathology specimens from the same region of the nasal cavity, demonstrated that patients with abnormal olfactory discrimination (UPSIT < 35) had increased frequency of inflammatory changes-including edema in the lamina propria-and increased presence of lymphocytes, macrophages, and eosinophils. 5 In a study by Zhao et al., histopathology was utilized to correlate olfaction with erosion of the olfactory cleft; however, this analysis only explained approximately 20% of olfactory variance. 34 These studies are limited by the semiquantitative nature of histologic-based studies, and for this reason our analysis used qRT-PCR over histopathologic analysis.
In other studies of nonolfactory mucosal tissue from CRS patients, increased mucosal eosinophil counts were associated with increased hyposmia and anosmia compared to those with normosmia, although not after adjusting for the presence of nasal polyps. 35, 36 These prior studies had not examined eosinophilia in tissue in the olfactory cleft and hypothesized that their results would correlate better if olfactory tissue were directly examined. Very recently, Schlosser found that olfactory cleft mucus IL-5 was correlated with olfactory performance, particularly identification and discrimination, in CRS patients. 27 Similarly, eosinophilia, as measured by ECP in nasal secretions, has been associated with airflowindependent reductions in olfactory thresholds and identification in patients with grass pollen allergies upon season onset. 37 As shown in this article and published research from our laboratory, IL-5, IL-13, the eotaxins, and eosinophilia are intercorrelated and are reflective of a type 2 inflammatory environment in CRSsNP and CRSwNP. 18, 29 Although the study by Schlosser suggested olfactory identification rather than threshold correlates best with type 2 inflammation, we interpret these studies as complementary evidence that type 2 inflammation has specific effects on olfactory function independent of airflow ( Fig. 1) .
Similar to other studies, we find that olfaction has several intercorrelated dimensions, including olfactory threshold and suprathreshold discrimination. 38 However, we find that threshold testing correlates with CLC better than discrimination, and it remained significantly correlated on multiple regression (Fig. 5) (Table IIa) . In examining the distribution of the data, it appeared that discrimination testing yielded more binary results, with participants demonstrating either near-normal or significantly impaired olfactory discrimination, whereas olfactory threshold was more linearly correlated with CLC gene expression in the ST. This finding is supported by Whitcroft et al, who recently published a large retrospective series evaluating tests of discrimination, threshold, and identification in patients with different etiologies of olfactory loss. 39 Their study further identified that patients with sinonasal inflammatory disease (mix of allergic rhinitis and CRS patients) were particularly impaired in olfactory threshold supporting our findings. Together, our data suggests that eosinophils have a more direct and specific role in CRS-associated olfactory dysfunction than commonly recognized. Importantly, studies of eosinophilic inflammation in other disease states suggest that eosinophils are frequently associated with neuropathology. For example, Costello et al. observed perineural eosinophilia was found in autopsy specimens of patients who died of status asthmaticus, and that the concentration of eosinophils clustered around nerve fibers was inversely correlated with M2 muscarinic receptor function in antigen-challenged guinea pigs. 40 In other studies, major basic protein, which is released from activated eosinophils, was shown to act as an antagonist to the M2 receptor. 41 Perineural eosinophilia has been further implicated in peripheral neuropathies in Churg-Strauss syndrome. 42, 43 There is also increasing evidence that treatments targeting mediators of type-2 eosinophilic inflammation have dramatic effects on improving inflammation in CRS patients. [44] [45] [46] In placebo-controlled randomized control trials of corticosteroids and mepolizumab and dupilumab for CRSwNP, olfactory improvements were highly significant. Interestingly, in the mepolizumab study the authors commented that olfaction durably improved, despite recurrence of all other CRS symptoms. Currently, the only approved medications for CRSwNP is topical mometasone, but this mode of delivery does not effectively reach the olfactory cleft, even in the absence of inflammatory changes. 47, 48 Our study highlights the profound eosinophilia of structures surrounding the olfactory cleft and illustrates the challenges for topical drug delivery to effectively treat this relatively inaccessible region of nasal anatomy.
CONCLUSION
Our study demonstrates that superior turbinates of CRSwNP patients had significantly increased eosinophilic inflammation. Furthermore, olfactory threshold deficits were significantly associated with superior turbinate eosinophilia even after controlling for nasal polyp status. This work provides direct evidence that CRS is a symptom of olfactory mucosal eosinophilia and that developmental therapeutics targeting type 2 eosinophilic inflammation are important for improving the treatment of CRS-associated olfactory dysfunction.
